Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.

Abstract:

:The objective of this study was to examine the safety and tolerability of duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, in a large cohort of elderly patients with major depressive disorder. Data were pooled from 8-week and 12-week, double-blind, randomized, placebo-controlled trials of duloxetine 60 mg/day (duloxetine=456; placebo=225). Discontinuation rates because of adverse events, treatment-emergent adverse events, abnormal changes in vital signs and weight, and changes in laboratory analytes were compared between treatments using a Cochran-Mantel-Haenszel test. Changes in laboratory analytes were analyzed using an analysis of variance model. Adverse event-related discontinuation rates were not significantly different between duloxetine and placebo (10.7 vs. 7.1%; P=0.13). Treatment-emergent adverse events for duloxetine of at least 5% and twice the rate of placebo were dry mouth, constipation, nausea, diarrhea, dizziness, and fatigue. Abnormal changes in vital signs and weight were not significantly different at any time between duloxetine and placebo. The mean changes in platelet count, alkaline phosphatase, potassium, random glucose, uric acid, and cholesterol were significantly different between duloxetine and placebo (P<0.05), but none of these differences were considered clinically relevant. The incidence of abnormal low sodium levels was not significantly different between treatments. These safety results may better inform clinicians providing individualized care to elderly patients with major depressive disorder.

authors

Oakes TM,Katona C,Liu P,Robinson M,Raskin J,Greist JH

doi

10.1097/YIC.0b013e32835b09cd

subject

Has Abstract

pub_date

2013-01-01 00:00:00

pages

1-11

issue

1

eissn

0268-1315

issn

1473-5857

journal_volume

28

pub_type

杂志文章,meta分析
  • Effects of risperidone on affective symptoms in patients with schizophrenia.

    abstract::The effects of risperidone on affective symptoms were determined by an analysis of pooled data from six double-blind trials of risperidone versus haloperidol in 1254 patients with chronic schizophrenia. Symptoms indicating mania were assessed by the Positive and Negative Syndrome Scale (PANSS) excitement and grandiosi...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/00004850-200015060-00005

    authors: Peuskens J,Van Baelen B,De Smedt C,Lemmens P

    更新日期:2000-11-01 00:00:00

  • The effects of d- and l-fenfluramine (and their interactions with d-amphetamine) on cortisol secretion.

    abstract::Twelve normal weight healthy male volunteers participated in a double-blind, placebo-controlled trial of the effects of d- and l-fenfluramine, d-amphetamine, and the interactions between the two isomers of fenfluramine with amphetamine, on cortisol secretion. d-Fenfluramine and d-amphetamine in combination produced th...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199300830-00001

    authors: Feeney S,Goodall E,Silverstone T

    更新日期:1993-10-01 00:00:00

  • Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.

    abstract::The treatment of negative symptoms of schizophrenia presents a major clinical challenge. This review examines the evidence pertaining to the efficacy, tolerability and safety of adding selective serotonin reuptake inhibitors (SSRIs) to antipsychotic agents in the treatment of negative symptoms in schizophrenia. Import...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-200311000-00001

    authors: Silver H

    更新日期:2003-11-01 00:00:00

  • Effect of trifluoperazine, a potential drug for tuberculosis with psychotic disorders, on the growth of clinical isolates of drug resistant Mycobacterium tuberculosis.

    abstract::The effect of the antipsychotic drug trifluoperazine (TFP) on the in-vitro growth of 50 clinical isolates of Mycobacterium tuberculosis was tested. Of these isolates, 29 were susceptible to all five of the antitubercular drugs isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide, and 21 were resistant to o...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199805000-00006

    authors: Gadre DV,Talwar V,Gupta HC,Murthy PS

    更新日期:1998-05-01 00:00:00

  • A molecular pathway analysis informs the genetic risk for arrhythmias during antipsychotic treatment.

    abstract::Arrhythmias are a frequent and potentially fatal side effect of antipsychotic treatment. Strict ECG monitoring and clinical interviews are the standards used to prevent arrhythmias. A biologic predictive tool is missing. The identification of a genetic makeup at risk of antipsychotic-induced arrhythmias is the aim of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000198

    authors: Drago A,Kure Fischer E

    更新日期:2018-01-01 00:00:00

  • Antidepressant-induced hypomania in obsessive-compulsive disorder.

    abstract::Out of ten consecutive patients with DSM-III-R obsessive-compulsive disorder without any previous history of bipolarity, three patients showed antidepressant-induced hypomania (clomipramine, one patient; fluvoxamine, two patients) within the first 5 to 8 weeks of the drug treatment. These data support the previous res...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199609000-00008

    authors: Rihmer Z,Barsi J,Belsõ N,Pestality P,György S

    更新日期:1996-09-01 00:00:00

  • Early onset of action of amineptine.

    abstract::A priority in the treatment of depression is to obtain rapid improvement at an early stage. Since depressed patients, who are often convinced that nothing can be done for them, may well have difficulty in adhering to the therapeutic management plan, they can be both uncooperative and neglectful of treatment measures. ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199707003-00005

    authors: Freeman H

    更新日期:1997-07-01 00:00:00

  • Antidepressant interactions with warfarin.

    abstract::The interactions between warfarin and antidepressants can have potentially serious consequences resulting from enhanced or reduced anticoagulant activity. Information about such interactions was obtained from a Medline and hand search of the published literature, and by directly contacting manufacturers. The different...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199803000-00006

    authors: Duncan D,Sayal K,McConnell H,Taylor D

    更新日期:1998-03-01 00:00:00

  • Carbamazepine compared to haloperidol in acute mania.

    abstract::In a double-blind, between-patient clinical trial carbamazepine (CBZ) (n = 8) was compared to haloperidol (HP) (n = 9) in patients presenting with mania (DSM III). Seven patients on HP and 2 on CBZ failed to complete 4 weeks treatment. In 4 of the HP group this was because of extrapyramidal side-effects (EPS). Two pat...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198907000-00005

    authors: Brown D,Silverstone T,Cookson J

    更新日期:1989-07-01 00:00:00

  • Somnambulistic-like behaviour in patients attending a lithium clinic.

    abstract::The prevalence of somnambulistic-like behaviour related to treatment with lithium alone or in combination with other psychotropic medications was evaluated in patients attending a lithium clinic. A written questionnaire on somnambulistic-like behaviour was completed by 389 patients. Information was provided on the tim...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Landry P,Warnes H,Nielsen T,Montplaisir J

    更新日期:1999-05-01 00:00:00

  • An open-label study of escitalopram in body dysmorphic disorder.

    abstract::Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.yic.0000194378.65460.ef

    authors: Phillips KA

    更新日期:2006-05-01 00:00:00

  • Pharmacotherapy for disordered sleep in post-traumatic stress disorder: a systematic review.

    abstract::Sleep disorders, such as insomnia and nightmares, are common problems in post-traumatic stress disorder (PTSD), exert a strong negative influence on the quality of life and are a great challenge for clinical psychiatry. Several studies have reported on the efficacy of drugs for the treatment of PTSD-related sleep diso...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-200607000-00001

    authors: van Liempt S,Vermetten E,Geuze E,Westenberg HG

    更新日期:2006-07-01 00:00:00

  • Effect of moclobemide on the psychophysiology of sleep/wake cycles: a neuroelectrophysiological study of depressed patients administered with moclobemide.

    abstract::The effects of moclobemide, 450 mg/day, on sleep were investigated in 12 patients with major depression. The study was carried out over six weeks, divided into three periods: (1) treatment for one week with placebo and measurement to obtain baseline values; (2) treatment with moclobemide for four weeks; and (3) one we...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-199300730-00009

    authors: Minot R,Luthringer R,Macher JP

    更新日期:1993-01-01 00:00:00

  • The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.

    abstract::Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor that is Food and Drug Administration approved for once-daily treatment of major depressive disorder in adults. Secondary and post-hoc analyses were carried out on data from a positive 10-week, randomized, dou...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000009

    authors: Montgomery SA,Mansuy L,Ruth AC,Li D,Gommoll C

    更新日期:2014-01-01 00:00:00

  • A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression.

    abstract::Fluvoxamine, a selective serotonin reuptake inhibitor, was investigated in a 6-week double-blind study among severely ill inpatients with DSM-III major depression. All but 1 patient also fulfilled criteria for melancholia. Following a 3-day placebo wash-out patients were randomly assigned to fluvoxamine, imipramine or...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198907000-00006

    authors: Feighner JP,Boyer WF,Meredith CH,Hendrickson GG

    更新日期:1989-07-01 00:00:00

  • Comorbidities in social phobia.

    abstract::In a sample of 2096 consecutive primary care patients recruited in the Paris region, social phobia was a highly prevalent disorder (5.1%). The most frequent comorbid condition was depressive episode, which affected 70% of patients with social phobia of early onset (at less than 15 years of age), while the highest asso...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199710006-00004

    authors: Lecrubier Y,Weiller E

    更新日期:1997-10-01 00:00:00

  • Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.

    abstract::Recently proposed criteria for remission by a 'Remission in Schizophrenia Working Group' have generated considerable interest. We assessed rates, predictors, and correlates of remission in a sample of patients with first-episode schizophrenia treated with injectable, long-acting risperidone. This allowed us to examine...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/YIC.0b013e32830c2042

    authors: Emsley R,Oosthuizen P,Koen L,Niehaus DJ,Medori R,Rabinowitz J

    更新日期:2008-11-01 00:00:00

  • Clinical utility of milnacipran in comparison with other antidepressants.

    abstract::The utility of milnacipran in the treatment of major depression has been the subject of an extensive clinical development programme. Comparative studies with tricyclic antidepressant drugs have demonstrated equivalent efficacy, with improved tolerability, in particular with respect to autonomic effects. In comparison ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-200206001-00006

    authors: Bisserbe JC

    更新日期:2002-06-01 00:00:00

  • Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.

    abstract::The use of certain atypical antipsychotics has been associated with metabolic disturbances. We have assessed the evolution of body weight and glycaemia during a 6-month randomized comparative trial of amisulpride and olanzapine. Three hundred and seventy-seven adult patients with schizophrenia were randomized to eithe...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/YIC.0b013e3280148c29

    authors: Peuskens J,De Hert M,Mortimer A,SOLIANOL Study Group.

    更新日期:2007-05-01 00:00:00

  • Depot antipsychotics in bipolar affective disorder.

    abstract::The effect of prophylactic treatment with depot antipsychotic drugs was examined in 16 patients with bipolar affective disorder. The frequency and duration of illness episodes occurring during depot treatment was compared to that which occurred when these patients were treated with other agents over a corresponding ti...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199300820-00007

    authors: White E,Cheung P,Silverstone T

    更新日期:1993-07-01 00:00:00

  • Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia.

    abstract::The aim of this study was to assess the response of social phobia (SP) symptoms to methylphenidate (MPH) treatment in children with attention deficit hyperactivity disorder (ADHD). Twenty-one ADHD patients with SP, aged between 8 and 18 years, received 12 weeks of MPH treatment. The severity of SP symptoms were assess...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000029

    authors: Golubchik P,Sever J,Weizman A

    更新日期:2014-07-01 00:00:00

  • The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder.

    abstract::In a randomized prospective clinical trial with an observation period of 2.5 years, a subgroup analysis was carried out for the 114 patients with bipolar I disorder (DSM-IV) regarding the prophylactic efficacy of lithium and carbamazepine. Treatment outcome was evaluated taking rehospitalization, recurrence, subclinic...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:

    authors: Greil W,Kleindienst N

    更新日期:1999-09-01 00:00:00

  • The effect of fluoxetine on sleep: a longitudinal, double-blind polysomnographic study of healthy volunteers.

    abstract::Fluoxetine, a selective inhibitor of serotonin (5-HT) uptake, was compared with placebo in a randomized double-blind longitudinal trial in 12 healthy volunteers. Sleep polygraphic recordings were performed at home twice before and once after 6 days of medication. After 6 days fluoxetine significantly decreased the amo...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199409000-00009

    authors: Vasar V,Appelberg B,Rimón R,Selvaratnam J

    更新日期:1994-09-01 00:00:00

  • The clock-drawing test as a possible indicator of acute psychosis.

    abstract::The clock-drawing test (CDT) is used widely to evaluate cognitive disorders, but its role in the assessment of psychotic disorders has not been studied. We sought to examine whether the CDT plays a role as an indicator of psychosis and to establish its sensitivity to clinical improvement of psychosis. The CDT was admi...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000118

    authors: Tene O,Sigler M,Shiloh R,Weizman A,Aizenberg D

    更新日期:2016-05-01 00:00:00

  • An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.

    abstract::The chronic course of major depressive disorder (MDD) often impedes the ability of patients to achieve full remission. Return of full functioning is a critical goal of antidepressant pharmacotherapy as the presence of residual depressive symptoms is associated with an increased risk of relapse. Treatment guidelines re...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/YIC.0000000000000121

    authors: Carrasco JL,Kornstein SG,McIntyre RS,Fayyad R,Prieto R,Salas M,Mackell J,Boucher M

    更新日期:2016-05-01 00:00:00

  • Depression in the community: the first pan-European study DEPRES (Depression Research in European Society).

    abstract::DEPRESS (Depression Research in European Society) is the first large pan-European survey of depression in the community. A total of 13359 of the 78463 adults who participated in screening interviews across six countries were identified as suffering from depression, a 6-month prevalence of 17%. Major depression account...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Lépine JP,Gastpar M,Mendlewicz J,Tylee A

    更新日期:1997-01-01 00:00:00

  • Differences in interactions of SSRIs.

    abstract::The SSRIs differ from each other with regard to their chemical structure, their pharmacokinetics and their potential for causing pharmacokinetic interactions through inhibition of species of the cytochrome P450 enzyme system. Cytochrome P450 (CYP) is a group of more than 30 different heme containing proteins in humans...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199809005-00009

    authors: Brøsen K

    更新日期:1998-09-01 00:00:00

  • Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.

    abstract::Recent evidence has demonstrated the efficacy of pegylated interferon-alpha (IFN-alpha) in treating hepatitis C virus infection. Neuropsychiatric complications commonly occur during the course of IFN treatment, with depressive symptoms usually appearing within the first 12 weeks. Few cases of the pegylated interferon-...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.yic.0000170263.46008.54

    authors: Sockalingam S,Balderson K

    更新日期:2005-09-01 00:00:00

  • Tardive dyskinesia in bipolar affective disorder: a catchment area study.

    abstract::The prevalence of tardive dyskinesia in a consecutive series of 69 patients with bipolar affective disorder admitted to a catchment area service was found to be 19%. Prevalence increased with age and was related to the age of onset of bipolar disorder and number of previous episodes. Patients with tardive dyskinesia w...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199100610-00006

    authors: Hunt N,Silverstone T

    更新日期:1991-04-01 00:00:00

  • Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.

    abstract::The present study aimed to compare health outcomes and tolerability according to antipsychotic medication (olanzapine, risperidone or an oral typical antipsychotic) after 6 months of treatment in a group of 919 schizophrenic patients who had never previously been treated with antipsychotics. Demographic and clinical p...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1097/00004850-200507000-00002

    authors: Gasquet I,Haro JM,Novick D,Edgell ET,Kennedy L,Lepine JP,SOHO Study Group.

    更新日期:2005-07-01 00:00:00